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ABSTRACT
Inhibition of gene expression can be achieved with
RNA interference (RNAi) or U1 small nuclear RNA—
snRNA—interference (U1i). U1i is based on U1 in-
hibitors (U1in), U1 snRNA molecules modified to
inhibit polyadenylation of a target pre-mRNA.
In culture, we have shown that the combination
of RNAi and U1i results in stronger inhibition of
reporter or endogenous genes than that obtained
using either of the techniques alone. We have now
used these techniques to inhibit gene expression in
mice. We show that U1ins can induce strong inhib-
ition of the expression of target genes in vivo.
Furthermore, combining U1i and RNAi results in
synergistic inhibitions also in mice. This is shown
for the inhibition of hepatitis B virus (HBV) se-
quences or endogenous Notch1. Surprisingly, inhib-
ition obtained by combining a U1in and a RNAi
mediator is higher than that obtained by combining
two U1ins or two RNAi mediators. Our results
suggest that RNAi and U1i cooperate by unknown
mechanisms to result in synergistic inhibitions.
Analysis of toxicity and specificity indicates that ex-
pression of U1i inhibitors is safe. Therefore, we
believe that the combination of RNAi and U1i will
be a good option to block damaging endogenous
genes, HBV and other infectious agents in vivo.
INTRODUCTION
Inhibition of the expression of toxic genes has great thera-
peutic potential. For most applications, gene expression in-
hibitionhasbeenobtainedusingRNAinterference(RNAi).
The inhibitors that mediate RNAi are double-stranded
small RNA molecules called small interfering RNAs
(siRNAs). siRNAs can be synthetic molecules or can be
produced in the cell from precursors called small hairpin
RNAs (shRNAs). For RNAi, exogenous siRNAs are
directed to the RNA-induced silencing complex (RISC),
bind the target with perfect complementarity and induce
target mRNA cleavage and as a result, target gene expres-
sionisinhibited(1).Inhibitionofgeneexpressioncanalsobe
performed using U1 small nuclear RNA—snRNA—inter-
ference (U1i) (2). U1i is based on a natural property of U1
snRNA ribonucleoprotein (U1 snRNP). When nucleotides
2–11ofU1snRNAbindtoatargetpre-mRNA,U1snRNP
inhibits pre-mRNA polyadenylation (3) (Figure 1a).
Without a polyA tail, the pre-mRNA fails to mature and
is rapidly degraded leading to reduced expression. U1i
requires expression of an exogenous 50-end mutated U1
snRNA designed to base pair to the 30-terminal exon or, in
caseofunsplicedtranscripts,toanypositionofatargetgene
(4,5). This U1 snRNA inhibitor (U1in) is expressed from a
plasmid that includes U1 snRNA promoter and terminator
sequences. Upon plasmid transfection, U1in is expressed,
binds target mRNA and blocks expression by hindering
polyadenylation (4,5). When target sites are located
outside the 30-terminal exon of a spliced transcript or
when they form secondary structures, inhibition is lost
(5,6). As in many cases, prediction of the secondary struc-
ture of long RNAs is not accurate and selection of good
target sites is a challenge that generally decides the success
of the technique. When appropriate targets are chosen,
U1in can inhibit the expression of reporter or endogenous
genesaftertransientorstabletransfections,suggestingalow
toxicity of this technique (5).
In tissue culture, the combination of RNAi and U1i
results in a stable inhibition of reporter or endogenous
genes, that is stronger than that obtained using either of
the techniques alone (2). The combination allows func-
tional inhibition with decreased doses of the inhibitors
and therefore it should serve to decrease unwanted
effects. This is therapeutically relevant and consequently,
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and U1i also leads to increased inhibitions in animal
models. In this work, we have evaluated the functionality
of U1i in vivo to target sequences of therapeutic relevance
such as those of hepatitis B virus (HBV) or endogenous
Notch1. To this aim, we have designed novel shRNAs and
U1ins against HBV expression. We show for the ﬁrst time
that U1i inhibits HBV expression after hydrodynamic in-
jection in mice. Besides, we show that a previously
validated U1in inhibits the expression of endogenous
Notch1 gene in mouse liver. Furthermore, the combin-
ation of U1in and shRNA results in synergistic inhibition
in mice. Surprisingly, inhibitions obtained by the combin-
ation of U1in and shRNA are higher than those obtained
by combination of two shRNAs or two U1ins. This
suggests that RNAi and U1i cooperate by an unknown
mechanism to result in synergistic inhibitions. We believe
that the combination of RNAi and U1i could serve as the
basis for a novel antiviral therapy against HBV and other
infectious agents and to obtain increased inhibition of the
expression of endogenous genes.
MATERIALS AND METHODS
Cell lines and DNA constructs
HuH7 cell line was obtained from the American Type
Culture Collection (ATCC) and cultured in Dulbecco’s
Modiﬁed Eagle Medium (DMEM), supplemented with
10% FBS and 1% penicillin-streptomycin, at 37 Ci na
5% CO2 atmosphere. All cell culture reagents were
obtained from Gibco BRL/Life Technologies. The
pCH Fireﬂy Luc vector (pCH-Fluc) was constructed
by replacing the preS2/S ORF region of pCH-9/3091
HBV replication competent plasmid with Fireﬂy
luciferase-encoding DNA (7). pNFkb-Luc (pNFkb
3xLuc; Clontech Co) was used to express Fireﬂy
luciferase under pNFkb promoter. Plasmid pRL-SV40
(Promega) was used as Renilla luciferase transfection
control. Plasmids expressing U1inaNotch1 and
shaNotch1 targeting Notch1 have been described (2).
pGemU1inaHBV plasmids, expressing U1ins that target
HBV genome (U1inaHBV) or mutant controls, were
cloned by ligation of base paired oligonucleotides with
the U1inaHBV sequences into the BclI–BglII site of
pGEMU1inWT (2) (Figure 2b). The U1 snRNA gene
expressed from this plasmid contains four point muta-
tions, but the resulting U1 snRNA is identical in function-
ality to endogenous U1 snRNA. Plasmids expressing
shRNAs that target the HBV genome (shaHBV) were
cloned by ligation of base paired oligonucleotides with
the shaHBV sequences into the HingIII–BglII sites of
pSuper (8) (Figure 2b). The 50-end of the shRNA starts
with the sense strand and is followed by a TTCAAGAGA
loop, the antisense strand and UU. The sense and anti-
sense strands have perfect complementarity and are 19nt
long.
Design of U1in target sites
The target sites for the U1ins were 10–11nt-long se-
quences chosen from conserved sequences in the HBV
genome. Besides, they fulﬁll at least two of the following
criteria. Firstly, they are accessible sequences according to
mfold (9). Note that mfold only predicts 2D structures
and not the potential occupancy of the target sites by
protein factors. UA, UB or UD accomplish this criterion.
Secondly, they are repetitive sequences in the HBV
genome according to SRF and therefore, in theory, they
could represent accessible sites susceptible to be bound by
cell regulators (10). Such a transient accessibility may be
advantageous as U1 snRNA binds pre-mRNA
co-transcriptionally, before other cellular factors may
interact with the target. UA, UC, UD or UE are repeti-
tive. Thirdly, they include putative target sites for liver
miRNAs according to several prediction programs or
they are targeted by functional siRNAs. This last criterion
indirectly measures accessibility of the target and has
proven useful in the design of U1in targeting Notch1
(2). UA, UB, UC and UF fulﬁll this criterion. Fourthly,
they contain sequence motifs signiﬁcantly associated with
antisense activity according to the rules described by
McQuisten and Peek (11). UB, UE and UF comply with
this condition. After this analysis, target sites found in the
30-terminal exon of unrelated genes were discarded to
reduce secondary effects. Redundancy was evaluated
using Basic Local Alignment Search Tool (BLAST) set
up to an Expect of 1000 and a word of 7 (12). Finally,
we rejected target sites with A at position 2 and therefore
Figure 1. Schematic of U1i and inhibition of Notch1 in vivo.( a)
Schematic of U1-mediated inhibition. U1in are exogenous 50-end
modiﬁed U1 snRNPs designed to base pair to the 30-terminal exon of
a target gene. In this study, the U1in binds Notch1 or HBV mRNA and
blocks expression by hindering polyadenylation (pA). (b)C 5 7 B L / 6m i c e
were injected with pNFkb-Luc plasmid (NFkBLuc) combined or not with
plasmids expressing shaNotch1 (sh), U1inaNotch1 (U1in) or the combin-
ation of both. Luciferase activity was measured in living mice with a
CCD camera at 4 days post-injection. Luciferase activity was quantiﬁed
and plotted. The SI and the statistical signiﬁcance are indicated.
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position 8 and T at position 9 which could allow
binding to U6 snRNP. Therefore the chosen target sites
have decreased potential to be removed by splicing after
binding to the U1in.
Cell transfections
Cells were transfected with calcium phosphate as
described (13). The conditions used were set up as
described (2). In brief, 150000 cells were transfected
with 0.75mg of pCH-Fluc, 0.25mg of pRL-SV40 and
1mg of the plasmid expressing the control inhibitor, a
combination of the plasmid expressing the control inhibi-
tor and the plasmid expressing the inhibitor or a combin-
ation of plasmids expressing different inhibitors (0.5mg
each). Mock transfected cells express a U1in of irrelevant
sequence. The total amount of transfected DNA was
maintained constant by adding a control plasmid. Cells
were harvested 72-h post-transfection.
Hydrodynamic tail vein injection and animal studies
This study was performed following the regulations of the
Animal Care Ethical Committee of the University of
Navarra. Six-to-eight-week-old male C57BL/6 mice
were injected with a total of 25mg of plasmids by hydro-
dynamic tail vein injection. Animals received in 3s a ﬁnal
volume of 2ml of physiological saline solution contain-
ing 10mg of plasmid expressing secreted alkaline phos-
phatase (pSEAP, Clontech) or 5mg of pCH-Fluc plasmid
or pNFkb-Luc combined or not with plasmids expressing
U1in and/or shRNA inhibitors. The only exception to
this rule was the injection of a total of 50mg that
included 30mg of pNFkb-Luc plasmid, where indicated.
The amount of plasmids expressing the inhibitors
used was generally 10mg of each plasmid unless
Figure 2. Schematic of the pCH-Fluc with the HBV genome expressing luciferase and the inhibitors that target HBV. (a) HBV genome was cloned
after a CMV promoter. The boxes represent the ORFs for Pre-core and core, polymerase (pol), X protein and PreS1, S2 and surface (S) antigen,
which has been replaced by Fireﬂy luciferase. The numbers show the position of the nucleotides that mark the start and the stop of each ORF of
HBV, starting at the ATG of Pre-core protein. The position where the luciferase sequence was inserted is also indicated. The last number indicates
the position of the cleavage and polyadenylation. The parallel lines indicate the four HBV transcripts. All transcripts share the same polyadenylation
sequences and therefore the polyA tail is initiated at the same position. Note that luciferase is probably translated from an RNA transcribed by the S
promoter (PreS2 and S proteins). However the upstream PreS1 promoter should generate a longer RNA which may encode for a PreS1/Luciferase
fusion protein that could show luciferase activity. The CMV promoter generates the longest RNA from which luciferase is unlikely to be translated.
The position of the inhibitors is shown at the bottom of the ﬁgure. (b) List of inhibitors used in this study. Position and sequence of the target is also
indicated.
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was maintained constant by adding an irrelevant carrier
plasmid.
Luciferase activity was measured at the indicated time
points in living mice with a CCD Camera (Xenogen,
Alameda, CA) 5min after intraperitoneal injection of
3mg of D-luciferin (Promega) and anesthetics (14).
Bioluminescence was measured for 5min until the
luciferase signal started to decrease and light intensity
was quantiﬁed as photons/s with Living Image software.
Blood samples were collected at the indicated time
points by retro-orbital bleed and animals were subse-
quently sacriﬁced. SEAP was measured with Phospha-
Light System following manufacturer’s instructions
(Applied Biosystems). Serum transaminases (alanine
aminotransferase and aspartate) were measured in blood
serum (ABX Diagnostics, Montpellier, France) in a Cobas
Integra autoanalyzer (Roche, Mannheim, Germany) (15).
Liver samples were parafﬁn-embedded and processed for
hematoxylin–eosin staining or snap-frozen in liquid
nitrogen and stored at  80 C.
Liver RNA analysis
Total RNA was isolated from liver samples using
TRIReagent following the manufacturer’s instructions
(Sigma). Two microgram of total RNA were DNAse
treated (Invitrogen) and reverse-transcribed with MMLV
reverse transcriptase (Promega) (16). U1 snRNA expres-
sion was quantiﬁed by real-time (RT)-PCR (BioRad) with
primers designed to detect exogenous U1 snRNA (U1Fw:
GATCTCATAGTTCCATGGCAGGGGAGATACCAT
and U1Rev: CGAGTTTGGCACATTTGGCC) and
normalized to mouse g-actin expression (ActFw ACTGC
GCTTCTTGCCGC and mActRev CATGACGCCCTG
GTGTC). PreS2/S Luc mRNA expression was quantiﬁed
from pA+ liver RNA isolated with PolyATract mRNA
Isolation System (Promega) by RT-PCR (BioRad) with
primers SFw: GGAAAACTCGACGCAAGAAA and
SRev: TACAGACTTGGCCCCCAATA. Oligo hybrid-
ization was performed at 60 C. Primer extension
analysis was performed with oligonucleotides designed
to detect sh1 (AAGGTCTTACATAAGAGG), sh2 (AA
GTTCAGTGGTTCGT) or U6 snRNA (TGCTAATCTT
CTCTGTATCGT). Oligonucleotides were labeled with
T4 polynucleotide kinase (New England Biolabs) in the
presence of [g-
32P]ATP. Primer extension conditions
were set up to work in the linear range (17). Six picomoles
of labeled oligonucleotides were incubated with 2mgo f
total RNA. Only 1mg of RNA was used in the primer
extensions with oligonucleotide U6. Samples were loaded
onto a 14% polyacrylamide gel and separated by electro-
phoresis. Gels were dried and exposed to a screen that was
developed in a Cyclone phosphorimager (Perkin Elmer).
In vitro luciferase activity measurements
Transfected cells and liver samples were processed for
protein isolation in 1  passive lysis buffer (Promega)
with 1  protease inhibitors (Roche). Luciferase activity
was measured using the Dual Luciferase System
(Promega) in a Berthold Luminometer (Lumat LB 9507)
as previously described (13). When extracts from trans-
fected cells were used, the values obtained for Fireﬂy
luciferase were corrected for equal transfection efﬁciency
with Renilla luciferase activity. Fireﬂy luciferase activity
measured in liver extracts is shown in relative light units
(RLU) permg of liver tissue protein as determined by the
Bradford assay.
Mathematical formulations
For the studies performed in vitro, the fold inhibition (FI)
for each inhibitor was calculated as the ratio of the
luciferase activity obtained in controls with no inhibitors
versus the luciferase activity obtained in cells expressing
the inhibitors studied. By deﬁnition, the control has an
inhibitory activity set to 1.0. For calculations with
values obtained from living animals, we made use of the
luciferase activity measured at Day 1 post-injection to cal-
culate the FI. Thus, the FI for each inhibitor was
calculated as the ratio of the luciferase activity obtained
in Day 1 versus the luciferase activity obtained in any
other time point. This helps to correct for small differences
in the efﬁciency of the hydrodynamic injection given that
inhibition was not detected at Day 1 with any of the in-
hibitors studied. Only small differences were observed
between the FI obtained with the two methods of calcu-
lation. The synergy index (SI) for the combination of
RNAi and U1 inhibition was calculated as previously
described (2). The critical value of SI is zero and indicates
an additive effect. When S is positive it shows synergism
and when negative it shows antagonism.
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
Statistical analysis was performed with ANOVA using the
GraphPad Prism Software. Statistically signiﬁcant differ-
ences are indicated with a star (P<0.05), two stars
(P<0.01) or three stars (P<0.001).
RESULTS
Effect of U1i and the combination of RNAi and U1i on
the expression of an endogenous gene in mice
We have recently shown that in tissue culture the combin-
ation of RNAi and U1i results in a stable inhibition of the
endogenous gene Notch1, which is stronger than that
obtained using either of the techniques alone (2).
We have now evaluated the inhibition of Notch1 in vivo
using the previously validated U1in (U1inaNotch1), or
shRNA (shaNotch1) targeting Notch1 or the combination
of both (2). To express the inhibitors in mouse liver,
we made use of hydrodynamic injections. Using this tech-
nique, co-transfection of several plasmids is highly
efﬁcient, but only 10–30% of the hepatocytes are trans-
fected. Therefore, Notch1 downregulation could not be
evaluated in liver extracts. Instead we introduced,
together with the inhibitors, a reporter gene that quantiﬁes
Notch1 activity. Notch1 expression increases NFkb
activity by facilitating its nuclear retention (18), resulting
in increased expression from NFkb-speciﬁc promoters.
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Fireﬂy luciferase under an NFkb speciﬁc promoter
(pNFkb-Luc). Decreased Notch1 in transfected cells
results in decreased NFkb activity and therefore in
reduced luciferase activity from pNFkb-Luc plasmid
(2,18). To test the system in vivo C57BL/6 mice (n=5)
were injected with 5mg of pNFkb-Luc plasmid mixed or
not with 10mg of plasmids expressing U1inaNotch1,
shaNotch1 or the combination of both. Luciferase
activity was quantiﬁed at Days 1 and 4 post-injection.
FI for each inhibitor was calculated as the ratio of the
luciferase activity obtained at Day 1 versus the luciferase
activity obtained at Day 4. Luciferase expression was
similar 1 day after injection and decreased drastically at
Day 4 in all groups (data not shown). Nevertheless,
co-expression of pNFkb-Luc with U1inaNotch1 or
shaNotch1 resulted in an inhibition of luciferase expres-
sion (Figure 1b). U1inaNotch1 and shaNotch1 inhibited
luciferase down to 56.5% (1.8-fold) or 68.5% (1.5-fold),
respectively. Surprisingly, the combination of
U1inaNotch1 and shaNotch1 resulted in a signiﬁcant in-
hibition of luciferase down to 15.4% (6.5-fold). A SI was
calculated as the ratio of the FI of the combination of
techniques minus the addition of the fold inhibitions
obtained with each of the inhibitors alone (2). The SI
was 0.97, higher than zero, indicating synergism. Similar
results were obtained when C57BL/6 mice (n=5) were
injected with 30mg of pNFkb-Luc plasmid mixed or not
with 10mg of plasmids expressing U1inaNotch1,
shaNotch1 or the combination of both and luciferase
activity was quantiﬁed at Days 1 and 3 post-injection
(FI of U1inaNotch1=1.8, FI of shaNotch1=1.6, FI
of the combination=4.4, SI=0.27). Differences in
luciferase expression were not observed compared to
control animals when a non-functional shRNA was used
alone or in combination with the U1inaNotch1.
Design of novel inhibitors against HBV expression and
analysis of the effect of the combination of RNAi
and U1i on HBV expression in culture
Strong inhibitions are desirable to block the expression of
viral genes for therapeutic applications. Thus, we decided
to evaluate the effect of the combination of RNAi and U1i
on the inhibition of expression from HBV sequences. HBV
is a non-cytopathic enveloped virus with a partly
double-stranded DNA genome of 3.2kbps. HBV repli-
cates by reverse transcription of an RNA intermediate,
the pregenomic RNA. Therefore, targeting HBV RNAs
does not only affect viral gene products but directly
impacts on viral replication. The viral genome contains
regulatory regions embedded in four open reading
frames that encode core, polymerase, surface (S) and X
proteins (Figure 2a). The HBV genome is compact in that
viral transcripts have overlapping sequences and share the
same polyadenylation signals. This facilitates the design of
inhibitors that target more than one transcript. To block
expression from HBV sequences, we constructed a
plasmid that expresses a shRNA whose functionality
against HBV expression has been established (19).
This shRNA, named sh1, targets a sequence located
within the X ORF (Figure 2). Following recommenda-
tions previously described (2), we also designed a novel
shRNA targeting HBV, named sh2. sh2 targets a region
upstream of the stop codon of the S gene. Finally, we
designed six U1in that target putative accessible sites of
the HBV genome (see ‘Material and Methods’ section for
details). The inhibitors were named UA, UB, UC, UD,
UE and UF. All the target sites are located in the S
region but are shared by other viral genes due to the
HBV compact genome (Figure 2). UA targets a site
upstream of the ATG of the S gene, UB site is up-
stream of the stop codon of the S gene and the remaining
U1in target sites are located downstream of the stop
codon of the S gene. In fact, the sequence bound by UF
is the most accessible region closest to the polyadenylation
signal according to mfold. This could be relevant for U1i
functionality as exogenous U1in inhibits polyA tail
addition.
The effect of the combination of the U1in and the
shRNAs targeting HBV was evaluated in cells expressing
pCH-FLuc. pCH-FLuc contains all the sequences from
HBV pCH-9/3091 with the S sequence replaced by the
Fireﬂy luciferase ORF (7) (Figure 2a). Expression from
pCH-FLuc has been shown previously to correlate well
with expression from the complete HBV genome and
allows a quantitative read out important for calculating
the strength of inhibitions (7,20). To evaluate expression
from HBV in the presence of the U1in, HuH7 cells were
co-transfected with pCH-FLuc and a plasmid expressing a
non-functional U1in control or the plasmids that express
each of the U1in aHBV. A plasmid that expresses Renilla
luciferase was also co-transfected as an internal control.
Cells were collected at 72-h post-transfection and
luciferase activity was evaluated in cell extracts. Renilla
luciferase activity was similar in all cases, suggesting com-
parable transfection efﬁciency and speciﬁcity of the inhibi-
tor for pCH-FLuc. The FI of luciferase exerted by the
U1in aHBV expression was calculated as the ratio of the
luciferase activity obtained in cells transfected with a
plasmid expressing a non-functional U1in control versus
the luciferase activity obtained in cells expressing each of
the U1in aHBV inhibitors. Luciferase activity was similar
in mock transfected cells and in cells expressing a
non-functional U1in. However, all U1in aHBV inhibited
expression from HBV sequences by 50–75% (2–4-fold,
Figure 3a). As described previously (2), inhibition of
Fireﬂy luciferase expression decreased when the amount
of plasmid expressing U1in aHBV was decreased to half in
the transfection mixture. Using half of the dose, UC failed
to inhibit expression from HBV sequences. The most
robust inhibitor was UF. There were no signiﬁcant differ-
ences among UA, UB, UD or UE.
In spite of the poor functionality of the lower dose of
U1in aHBV, we tested whether the inhibition increased
when these inhibitors were co-expressed with shRNAs tar-
geting HBV. To this end, cells were treated as before with
the exception that pCH-FLuc was co-transfected with a
combination of a control plasmid and a plasmid express-
ing each U1in aHBV, sh1 or sh2 or with the combination
of a plasmid expressing an U1in aHBV and a plasmid
expressing a shRNA aHBV in all possible combinations.
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was measured in cell extracts and FI was calculated as
described above. The combination of the shRNAs with
the non-efﬁcient UC resulted in an inhibition similar to
that obtained with the shRNAs alone (Figure 3b and c).
Thus, UC is not a functional inhibitor on its own or
after combination with the shRNAs. However, the best
inhibition of luciferase was observed when any of the
other U1in aHBV were co-expressed with the shRNAs.
Combination of U1inaHBV with sh2 was better than
with sh1, as the former leads to synergistic increased in-
hibition with all functional U1in aHBV tested.
Effect of UA and the combination of RNAi and UA on
HBV expression in mice
To test the system in vivo we made use of hydrodynamic
injections. We ﬁrst analyzed the luciferase expression from
pCH-Fluc in mice. C57BL/6 mice (n=5) were injected
with pCH-Fluc and luciferase activity was quantiﬁed
with a CCD camera at Days 1, 3, 5, 7, 9, 11 and 14
post-injection. Luciferase expression from pCH-Fluc was
detected at Day 1 and was relatively stable until Day 7
post-injection (Supplementary Figure S1). Therefore, this
time was chosen as the end-point for our experiments. We
decided to evaluate ﬁrst the effect in vivo of one of the
U1inaHBV. Thus, C57BL/6 mice (n=5) were injected
with 5mg of pCH-Fluc plasmid mixed or not with 10mg
of plasmids expressing UA, sh1, sh2 or the combination of
UA with sh1 or sh2. Luciferase activity was quantiﬁed at
Days 1, 3, 5 and 7 post-injection. FI for each inhibitor was
calculated as the ratio of the luciferase activity obtained at
Day 1 versus the luciferase activity obtained at any other
time point. Animals were sacriﬁced at Day 8 for further
analysis. Luciferase expression in all groups was similar
1day after injection, indicating that inhibition is not
detected at this time point (Figure 4a and b).
Co-expression of HBV sequences encoding luciferase
with sh1 or sh2 resulted in a dramatic inhibition of
luciferase expression (sh1: inhibition of 93.2%; FI=14.7
and sh2: inhibition of 96.9%; FI=32.8) (Figure 4). As
observed in culture, sh2 was more potent than sh1.
Inhibition by both shRNAs targeting HBV was detected
at 3 days post-injection and gradually increased until the
end of the study. Surprisingly, in mice, inhibition with UA
was as potent as with the shRNAs (inhibition of 97.0%;
FI=33.3). Furthermore, the combination of UA and sh1
or sh2 resulted in the strongest inhibition of expression
from HBV sequences (UA+sh1: inhibition of 98.8%;
FI=83.7; UA+sh2: inhibition of 98.7%; FI=81.9).
Further analysis revealed that the combination of UA
and sh1 or sh2 resulted in a statistically signiﬁcant
stronger synergistic inhibition of HBV expression as
compared to that obtained using either of the inhibitors
on their own (Figure 4c). Similar results were obtained
when luciferase activity was evaluated in vitro using liver
extracts from animals sacriﬁced 8 days
post-hydrodynamic injection (Figure 4d). The inhibition
obtained was similar in animals expressing UA, sh1 or
sh2. Again, co-expression of UA and sh1 or sh2 resulted
in a statistically signiﬁcant stronger inhibition of HBV
expression.
To set up the best conditions for inhibition, similar
experiments were carried out using decreasing
amounts (10, 5 and 2.5mg) of plasmids expressing sh1,
sh2 or UA (Supplementary Figure S2). A 5or2.5mgo f
plasmids expressing sh1 or sh2, respectively, resulted in
inhibitions similar to those observed with 10mgo f
plasmid. Inhibition by UA was more sensitive to the use
of lower doses of plasmid. Non-signiﬁcant differ-
ences were observed between 10 or 5mg of plasmids ex-
pressing UA combined with the same amount of
plasmids expressing any of the shRNAs. However, inhib-
ition obtained by combination of 10mg of plasmid
expressing UA and 10mg of plasmid expressing any
shRNA was the fastest and tended to last longer
(see in vitro analysis in Supplementary Figure S2f).
Therefore, we decided to use these conditions unless spe-
ciﬁcally indicated.
Figure 3. Analysis of U1ins targeting HBV in culture. (a) Expression
inhibition of HBV sequences with U1i. Luciferase activity was
measured in HuH7 cells co-transfected with pCH-FLuc and a control
plasmid or 1mg or 1/2mg of each plasmid expressing U1inaHBV. (b and
c) Effect of the co-expression of U1inaHBV and shRNAs aHBV on the
expression from HBV sequences. Luciferase activity was measured as
before but in cells co-transfected with pCH-FLuc and 1/2mgo fa
plasmid expressing a control U1in, each U1inaHBV, sh1 (b), sh2 (c)
or a combination of 1/2mg of a plasmid expressing an U1inaHBV and
1/2mg of a plasmid expressing sh1 (b) or sh2 (c). The FI is indicated for
each case. Note that the scale is different for each ﬁgure. The SI is
indicated at the top of the corresponding bars. Synergistic inhibitions
are highlighted with an SI in bold. Data are mean±SD from a
minimum of ﬁve independent experiments.
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HBV expression in mice
The good performance of UA or the combination of UA
and shRNAs aHBVs in vivo encouraged us to test the
effect of the functional inhibitors UB, UD, UE or UF
on expression from HBV sequences in mice. C57BL/6
mice (n=5) were injected with pCH-Fluc plasmid
combined or not with plasmids expressing each one of
these U1in aHBV and/or each shRNA aHBV in all
possible combinations and luciferase activity was
evaluated. The experiments performed were similar to
those described above. Luciferase expression in all
groups was generally similar 1 day after injection,
indicating that inhibition was not detected at this time
point (Figure 5a–c). Functionality of the shRNAs aHBV
has been already described. UF is also a good inhibitor of
HBV expression (inhibition of 92.1%; FI=12.6). In
general, the results obtained in culture do not help to
predict the outcome in mice. In culture UF was stronger
than UA while in vivo UA was the strongest. In culture
UA, UB, UD and UE were similar whereas in mouse UB,
UD and UE were not functional. UC was not functional
neither in vitro nor in vivo (data not shown). UB, UC, UD
and UE neither inhibited luciferase expression on their
own nor in combination with any shRNA aHBV tested.
However, the combination of UA or UF with the shRNA
aHBVs resulted in increased synergistic inhibitions
(UF+sh1: inhibition of 98.4%; FI=63.7; UF+sh2: in-
hibition of 98.5%; FI=67.2). We also quantiﬁed the tran-
scripts that may encode for luciferase (PreS2/SLuc mRNA
and PreS1Luc mRNA) in RNA isolated from liver
extracts obtained from animals sacriﬁced 8 days
post-hydrodynamic injection. The results show a synergis-
tic decrease in the accumulation of PreS2/SLuc and
PreS1Luc mRNAs when UF and sh2 were combined
compared to that observed when only UF or sh2 were
used (Figure 5d and Supplementary Figure S3). These
results suggest that the inhibitors alone or in combination
affect the stability of the target mRNA and do not act at a
translational level. Similar results were obtained when
luciferase activity was evaluated in vitro using liver
extracts (Figure 5e).
Analysis of the speciﬁcity of U1in mediated inhibition
The inhibition observed with UA and UF seems to be
speciﬁc since the expression of other exogenous U1ins,
Figure 4. Analysis of the inhibition of luciferase expression from HBV by RNAi and UA in mice. C57BL/6 mice were injected with pCH-Fluc
plasmid (HBVLuc) combined or not with plasmids expressing UA, sh1, sh2 or the combination of UA and sh1 or UA and sh2. Luciferase activity
was measured in living mice with a CCD camera at the indicated times post-injection (a–c) or in liver extracts obtained 8 days post-injection (d).
Representative pictures are shown (a). The color scale used is identical for all images and is shown at the bottom. Luciferase activity was quantiﬁed
and plotted (b) or used to calculate the FI and SI (c). RLU indicates relative light units (d). Data are mean±SD from three independent
experiments. Signiﬁcant differences are indicated with asterisks. Note that in b signiﬁcant differences shown compare luciferase activity obtained
with the best inhibitor, either UA or shRNA, on its own with the luciferase activity obtained by combination of UA and the shRNA.
PAGE 7 OF 14 Nucleic AcidsResearch, 2012,Vol. 40,No. 1 e8Figure 5. Effect of U1ins and shRNAs targeting HBV in mice. C57BL/6 mice were injected with pCH-Fluc plasmid (HBVLuc) combined or not with
plasmids expressing UB, UD, UE, UF and/or sh1 (a, c and e) or sh2 (b–e). Luciferase activity was quantiﬁed in living mice with a CCD camera at
the indicated times post-injection (a–c) or in liver extracts obtained 8 days post-injection (e). PreS2/S Luc mRNA was quantiﬁed by RT–PCR from
the same extracts (d). The relative number of copies of PreS2/S Luc mRNA obtained from 67ng of pA+mRNA compared to a standard plasmid is
shown. FI was calculated as described (c). The SI has been calculated for the combination of U1in and shRNA (c and d). RLU indicates relative
light units (e). Data are mean±SD from at least two independent experiments. Signiﬁcant differences are indicated with asterisks. Statistical analysis
shown compares animals treated with the combination of U1in and shRNA with animals treated with the best inhibitor alone (a, b and d) or with
either of the inhibitors on its own (e). Statistical analysis of UB, UD and UE resulted in non-signiﬁcant differences.
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pression in vivo. To further evaluate speciﬁcity, we ﬁrst
quantiﬁed SEAP in serum obtained from C57BL/6 mice
(n=5) at different times post-hydrodynamic injection of a
plasmid expressing pSEAP together with HBVLuc, as a
negative control, UA, UF, sh1 or sh2 (Figure 6a). SEAP
decreased with time with similar kinetics in all cases. This
indicates that SEAP expression was not affected by UA or
UF. Similar results were obtained when SEAP was
co-expressed with other U1in (data not shown).
Finally, to determine whether the 50-terminal sequence
of UA or UF was important for inhibition of luciferase
expression, we constructed mutated versions named
UAMut and UFMut, in which the two central nucleotides
of the target complementary sequence have been
exchanged by their complementary counterparts (Figure
2b). Luciferase expression from HBVLuc was evaluated
in vitro when UA, UAMut, UF and UFMut were ex-
pressed in HuH7 cells alone or in combination with
plasmids expressing sh1 or sh2 (Figure 6b and c) and
in vivo after hydrodynamic injection of C57BL/6 mice
(n=5) (Figure 6d and e). As expected, UAMut and
UFMut failed to inhibit luciferase expression in tissue
culture and in mouse liver.
Figure 6. Analysis of the speciﬁcity of U1ins targeting HBV. (a) C57BL/6 mice were injected with pSEAP and pCH-Fluc plasmid (HBVLuc)
combined or not with plasmids expressing UA, UF, sh1 or sh2. SEAP was quantiﬁed in blood extracted at the indicated times post-injection.
SEAP RU indicates relative units of SEAP. (b and c) Luciferase activity was evaluated in HuH7 cells treated as described in Figure 3 with the
exception that the cells were transfected with plasmids expressing inhibitors UA, UAMut, UF and UFMut alone (b) or in combination with sh1 or
sh2 (c). Cells expressing sh1 or sh2 alone were also evaluated (c). The FI is indicated for each case. Note that the scale is different for each ﬁgure.
The SI is indicated at the top of the corresponding bars. Synergistic inhibitions are highlighted with an SI in bold. (d and e) C57BL/6 mice were
injected with pCH-Fluc plasmid (HBVLuc) combined or not with plasmids expressing UA, UAMut, UF and UFMut. Luciferase activity was
quantiﬁed in living mice with a CCD camera at the indicated times post-injection (d) or in liver extracts obtained 8 days post-injection (e). RLU
indicates relative light units. Data are mean±SD from at least two independent experiments.
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kind on HBV expression in vivo
The increased inhibition observed by combination of
RNAi and U1i could simply be the result of the combin-
ation of two different inhibitors or even the result of the
increased dose of inhibitors. We rationalized that
increasing the dose of inhibitors of the same kind should
have, at most, an additive effect (i.e. SI= 0). However, we
decided to verify this experimentally. First, we tested the
effect of higher doses of a single inhibitor on luciferase
expression from HBV sequences in vivo. To this aim,
luciferase activity was evaluated in C57BL/6 mice
(n=5) injected with pCH-Fluc and 10 or 20mgo f
plasmids expressing sh1, UA, UD or UF. Analysis
revealed that luciferase expression was similar in animals
that received 10 or 20mg of plasmids expressing the inhibi-
tors (Figure 7a–d).
Further, we tested the effect of the combination of two
inhibitors of the same kind. In this case, luciferase activity
was evaluated in C57BL/6 mice (n=5) injected with
pCH-Fluc and 10mg of plasmids expressing sh1, sh2,
UA, UF or the combination of sh1 and sh2 (Figure 7e)
or UA and UF (Figure 7f). The results show that the
combination of inhibitors of the same kind results in
non-statistically signiﬁcant increased inhibition
compared to that obtained using either of the inhibitors
on their own. Increased inhibitions obtained with the com-
bination of sh1 and sh2 or UA and UF generally represent
additive effects (SI=0). In all cases, the combination of
U1i and RNAi resulted in stronger inhibitions than the
combination of two shRNAs or two U1ins (Figures 4
and 5 and data not shown).
Analysis of the accumulation of inhibitors in vivo after
combination of RNAi and U1i
Even when the snRNA and the shRNA processing
pathways seem to have little in common, one of these
could activate the other by an unknown mechanism.
This could result in an increased accumulation of one
of the inhibitors and, therefore, in increased inhibition.
Figure 7. Effect of combining HBV inhibitors on luciferase expression in vivo.( a–d) Effect of increased doses of inhibitors. C57BL/6 mice were
injected with pCH-Fluc plasmid (HBVLuc) combined with 10 or 20mg(  2) of plasmids expressing sh1 (a), UA (b), UD (c) or UF (d). (e and f)
Effect of combining inhibitors of the same kind. C57BL/6 mice were injected with pCH-Fluc plasmid (HBVLuc) combined with 10mg of plasmids
expressing sh1, sh2 or the combination of sh1 and sh2 (e) or UA, UF or the combination of UA and UF (f). Luciferase activity was quantiﬁed in
living mice with a CCD camera at the indicated times post-injection. FI and SI were calculated as described. Data are mean±SD from two
independent experiments.
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of the inhibitors in mouse liver. Processed sh1 and sh2 was
evaluated by primer extension of RNA isolated from liver
extracts obtained 8 days after hydrodynamic injection
(Figure 8a). As expected, animals treated with 20mgo f
plasmid expressing sh1 or sh2 showed twice the amount
of inhibitor than animals treated with 10mg of plasmid.
This conﬁrms that the primer extension is sensitive to
detect increased concentration of inhibitors. However,
the amount of inhibitor was similar in animals expressing
the RNAi inhibitor alone or in combination with an U1in.
Thus, the increased inhibition observed by combination of
RNAi and U1i is not caused by an increased accumulation
of shRNA.
To measure hepatic U1in aHBV, expression of exogen-
ous U1 snRNA was evaluated by quantitative RT-PCR in
liver extracts obtained 8 days after hydrodynamic injec-
tion. Note that the exogenous snRNAs differ from the
endogenous in the 50-end and in four internal point muta-
tions that do not disturb functionality and allow easy
quantiﬁcation. A quantitative RT-PCR of actin mRNA
was performed in parallel to correct for small loading dif-
ferences. As expected, exogenous U1 snRNA was only
detected in animals treated with plasmids expressing
U1in. Interestingly, there were no signiﬁcant differences
in levels of exogenous U1in between animals treated
with plasmids expressing U1in alone or in combination
with shRNA (Figure 8b). Levels of UA, UB, UF,
UAMut and UFMut were similar in all animals that ex-
pressed these small RNAs (Figure 8b and Supplementary
Figure S4). Surprisingly, some non-functional U1in
tended to have a lower accumulation in vivo. Levels of
UD and UE were reproducibly lower than a threshold
of 50000 relative copies.
To determine whether the low expression of UD and
UE was intrinsic to the constructs that express these
RNAs, HuH7 cells were transfected with plasmids ex-
pressing UD, UE or UF and exogenous U1in was
evaluated in cell extracts as described. The expression
levels of these constructs were similar in tissue culture
(Figure 8c). Finally, we evaluated DNA levels of the
plasmid that express U1in by quantitative PCR in liver
extracts obtained 8 days after hydrodynamic injection.
All animals showed similar levels of U1in expressing
plasmids (Supplementary Figure S5). This indicates that
the lower accumulation of UD and UE does not result
from a decreased stability of the plasmids that express
these inhibitors in mouse liver.
Figure 8. Quantiﬁcation of shRNAs and U1in targeting HBV. (a) Quantiﬁcation of shRNAs. sh1 and sh2-derived siRNAs were visualized by
extension with a sh1 (lanes 1–10) or sh2-speciﬁc (lanes 11–20) labeled primer of RNAs isolated from the liver of C57BL/6 mice injected with
pCH-Fluc plasmid (HBVLuc, lanes 2 and 12) alone or combined with 20 or 10mg of plasmids expressing sh1 or sh2 or with 10mg of plasmids
expressing sh1 or sh2 and 10mg of plasmids expressing UA or UF. U6 snRNA was also evaluated by primer extension as a loading control (bottom).
Two shRNA-expressing animals were evaluated for each condition. Labeled primer incubated with buffer was run in parallel (Oligo). (b)
Quantiﬁcation of U1in in vitro and in vivo. Exogenous U1in expression was quantiﬁed by RT-PCR from liver extracts obtained as described in
Figure 5 (b) or extracts from HuH7 cells transfected with plasmids expressing UD, UE or UF as described in Figure 3 (c). Actin mRNA was also
quantiﬁed to allow comparison between different samples. Data are mean±SD from ﬁve (a) or six (b) samples from two independent experiments.
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Our study shows that expression of U1ins can result in
strong inhibition of the expression of target genes in
mice. Furthermore, the combination of U1i and RNAi
can result in synergistic inhibition in animal models,
relevant to decreasing expression from sequences of thera-
peutic relevance. In particular, we tested inhibition of en-
dogenous Notch1 and inhibition of expression from HBV
sequences. Notch1 downregulation was evaluated by
measurement of Notch1 effect on NFkb (2,18). Thus, we
could determine the functional relevance of Notch1
downregulation. However, this method could not be
used to quantify strong inhibitions of Notch1 expression,
as NFkb activity is only increased linearly when Notch1 is
expressed over a relatively high threshold level (18).
Therefore, we evaluated inhibition of luciferase expression
from HBV sequences, which allowed quantiﬁcation within
a broad linear range. To this end, we used a plasmid that
contains all HBV sequences except for the ORF of the S
gene, which has been replaced with the ORF of Fireﬂy
luciferase (Figure 2a). This plasmid, pCH-Fluc, was pre-
viously used to analyze RNAi-mediated inhibition in
culture (7,20). Here we show that pCH-Fluc can also be
used in vivo. When we introduced pCH-Fluc into mice by
hydrodynamic injection, luciferase activity was stable for
one week and decreased slowly at later times
(Supplementary Figure S1). This is different to what has
been observed in mice with expression from other viral
promoters such as CMV or SV40, which are inactivated
very rapidly (21) (Figure 6a). Actually, pCH-Fluc also
has a CMV promoter that drives the expression of the chi-
meric core/pol-luciferase mRNA (Figure 2a). This long
chimeric mRNA was not detected by quantitative
RT-PCR of pA+ RNA isolated from the liver 8 days
after hydrodynamic injection of pCH-Fluc (data not
shown). As relatively constant levels of luciferase activity
were detected until this time point, we conclude that the
chimeric core/pol-luciferase mRNA does not contribute
signiﬁcantly to luciferase activity. Instead, luciferase is
probably translated from an RNA transcribed from
the S promoter that results in translation of PreS2 and S
proteins from HBV genome. The upstream PreS1
promoter should generate a longer RNA which may
encode for a PreS1/Luciferase fusion protein that could
also show luciferase activity. One day after hydrodynamic
injection of pCH-Fluc, luciferase activity was similar in
control animals and in animals co-injected with plasmids
expressing functional shRNA or U1in targeting HBV
(Figures 4–7 and Supplementary Figure S2). This
suggests that luciferase is expressed very rapidly and that
the effect of the inhibitors is only detected at later time
points. We believe that measurement of luciferase from
pCH-Fluc in vivo and in vitro is a good method to
quantify the effect of inhibitors that target HBV se-
quences. However, further experiments are required to de-
termine whether the inhibitors affect the stability of
transcripts expressed from the complete viral genome
and have an impact on viral viability.
In this study we evaluated the effects in tissue culture
and in mice of six novel U1ins, designed following our best
criteria for functionality (see ‘Materials and Methods’
section for details). We also constructed two plasmids
that express shRNAs targeting HBV. In culture, the
U1ins tested were worse inhibitors than the shRNAs
and showed poor functionality when a lower dose was
used (Figure 3), indicating that the design of functional
U1in could require further development. Surprisingly, in
mice, some U1ins were functional and resulted in similar
inhibition to that observed with shRNAs (Figure 5c).
Inhibition is speciﬁc as functional U1in did not affect ex-
pression of reporter genes that lack a target sequence
(Figure 6a). Furthermore, mutant versions of functional
U1in failed to inhibit luciferase expression from HBV
(Figure 6).
On the other hand, some U1in were functional in tissue
culture and not in mouse. UA, UB, UC, UD and UE
showed similar efﬁcacy in HuH7 cells, but only UA was
functional in the liver (Figures 3–5). This was not
observed with the shRNAs analyzed, which were function-
al both in vitro and in vivo. One of the inhibitors, UB,
accumulated to normal levels in the liver where it was
not functional. We speculate that UB and other U1in
may be more sensitive to target accessibility than
shRNAs. Some of the U1in target sites may be accessible
in some cells (such as immortalized HuH7 cells) and not in
others (such as primary mouse hepatocytes). In the case of
UD and UE, the lack of functionality correlated with low
levels of accumulation of the inhibitor. In HuH7 cells UD
and UE were expressed to similar levels as UF while in
liver cells they showed lower levels than any other U1in
tested (Figure 8). This is particularly dramatic in the case
of UD whose levels were 2 logs lower than those of UF.
Transcription or stability of UD could be lower in
mice for unknown reasons. Alternatively, UD expressing
cells could be eliminated due to toxicity caused by
UD-mediated off-target inhibition. This does not seem
to be the case. UD-treated liver cells expressed similar
levels of luciferase as control cells and similar levels of
the U1in expressing plasmid as cells treated with the func-
tional UF (Figure 5 and Supplementary Figure S5).
Furthermore, we tested safety of the expression of UD
and other U1ins, shRNAs and combinations of both
and we found no signs of toxicity for the entire period
of observation (data not shown). Necropsies performed
in animals sacriﬁced 8 or 15 days after hydrodynamic in-
jection revealed no apparent systemic abnormalities.
Similar levels of ALT and AST transaminases were
detected in the serum of all animals (data not shown).
Liver sections were stained with hematoxylin–eosin and
subjected to histopathological analysis. Liver histology
conﬁrmed the absence of malignant or premalignant
lesions, lack of inﬂammation, necrosis or apoptosis and
showed appropriate liver architecture in all animals
(data not shown). Further experiments will be required
to address the safety of U1i when inhibitors are ubiqui-
tously expressed at high levels and for longer periods of
time. In fact, it has been recently published that toxicity
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pressed from adeno-associated viral vectors for 2 months
(22). This, together with our results, is encouraging
for the use of the combination of U1i and RNAi for
gene therapy applications. Also, more experiments are
required to address why some inhibitors are functional
in culture and not in mouse liver. In this work, we
show that three U1in (U1inaNotch1, UA, UF) worked
in vivo out of the six that show synergistic inhibitions in
culture when combined with shRNAs. Until the major
reasons that drive the lack of functionality in vivo of
these U1ins are understood and U1in able to work
in vivo can be designed, we recommend that the users of
this technology test in vivo at least three U1in functional in
culture.
Our results show a synergistic effect of the combination
of RNAi and U1i both in culture and in mice, although
synergism is not observed with all possible combinations
between U1in and shRNAs. In fact, we had previously
reported that poor inhibitors do not show synergism in
cultured cells (2). In mice, UA and UF are strong inhibi-
tors and when co-expressed with sh1 or sh2 result in a
60–80FI of HBV expression (Figure 5c). Similar results
were observed when UA or UF were combined with
another shRNA targeting HBV (data not shown).
Surprisingly, combination of two shRNAs or two U1ins
resulted in lower inhibition that the combination of U1i
and RNAi. The former represented an additive effect
while the later showed synergistic inhibition. Therefore,
synergism between U1i and RNAi indicates that these
mechanisms can work together to produce higher levels
of inhibition than those obtained when the techniques
are used independently. Further experiments will be
required to clarify the exact molecular mechanism
underlying this phenomenon. Our results indicate that
the combination of techniques does not lead to a higher
accumulation of U1in or shRNA molecules that could
account for the synergism observed.
The increased inhibitions obtained by combining U1i
and RNAi could be of interest to decrease the dose of
each inhibitor and still obtain functional inhibitions with
lower secondary effects (23–27). Besides, the combination
could be used to obtain a high inhibition which is manda-
tory, for instance, when targeting a replicative viral RNA.
An inhibition of 97.5% (40-fold) or of 98.75% (80-fold)
may have the same functional effect in the inhibition of
endogenous genes such as Notch1. However, in the cases
of viruses replicating via RNA, such as HCV, HIV or
HBV, an inhibition of 97.5% would leave twice as many
viral RNA copies than an inhibition of 98.75%. The pro-
duction of few viral particles from a partially inhibited
infected cell may be sufﬁcient to sustain the viral infection
in the patient. Furthermore, the combination of RNAi
and U1i could serve to decrease the possibility of viral
escape by selection of viruses resistant to a single inhibitor.
This is important for HBV infection as HBV polymerase
lacks proofreading activity resulting in rapid mutagenesis
of HBV and emergence of resistant variants against
current treatments. In conclusion, we believe that
combination of RNAi and U1i could be the basis for a
novel therapy for the treatment of HBV and, possibly,
other infections.
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